biliary tract malignancies | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

12,506 results for “biliary tract malignancies”

Trials

View all 9038 →

Not yet recruiting

Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies

34 participants · First posted May 20, 2026

Not yet recruiting

Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies

49 participants · First posted Mar 16, 2026

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

35 participants · First posted Dec 26, 2023

Drugs

View all 192 →

Biliary tract cancer diagnostic(J-Pharma Co., Ltd.)

Haem Malignancies(Evariste)

Complex Urinary Tract Infections(Phaxiam)

Organizations

View all 33 →

TRACT Therapeutics, Inc.

United States

Institute of Liver & Biliary Sciences

India

INSTITUTE OF LIVER AND BILIARY SCIENCES

India

News

View all 3243 →

Allist's Jetientai (tengotinib) included in CSCO diagnosis and treatment guidelines

ctDNA Testing Shows Promise as Early Predictor of Biliary Tract Cancer Recurrence

FDA Approves Zanidatamab (Ziihera) for HER2-Positive Biliary Tract Cancer

Page 1 of 1251